New York: Taro Pharmaceutical Industries, a subsidiary of Sun Pharmaceutical, on Thursday announced that its board of directors has appointed Abhay Gandhi as interim chief executive officer, effective January 1, 2017.
Gandhi currently serves as CEO of Sun Pharmaceutical Industries’ North America operations. Taro’s board of directors has also nominated Gandhi to its board.
Prior to joining Sun Pharma’s North America business, Gandhi held several leadership positions within Sun Pharma over the last 20 years, including most recently as CEO of its India business. His leadership enabled the India business to grow more than three-fold in revenue within a short span of three years.
Gandhi will serve as Interim CEO of Taro Pharmaceutical during the period from Kal Sundaram’s departure at the end of this year and until the arrival in April 2017 of Uday Baldota, Taro’s recently appointed CEO.
On November 22, Taro Pharmaceutical had announced the appointment of Baldota as chief executive officer and as a nominee to Taro’s Board of Directors. Baldota is expected to begin his role as CEO on or about April 1, 2017.
Baldota currently serves as executive vice president and chief financial officer of Sun Pharmaceutical Industries. He has an MBA from Indian Institute of Management, Ahmedabad and a chemical engineering degree from Indian Institute of Technology, Delhi.
Dilip Shanghvi, chairman, Taro Pharmaceutical, said, “I am confident that Uday’s experience, vision and leadership, will enable Taro to continue its growth path and deliver superior stakeholder value.”
Taro Pharmaceutical is a multinational, science-based pharmaceutical company dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the high quality healthcare products.